RINVOQ 15 mg Upadacitinib

RINVOQ is a prescription medication containing the active substance upadacitinib. It belongs to a class of drugs known as Janus kinase (JAK) inhibitors, used to treat various inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis.

The brand was developed and is owned by AbbVie, a global biopharmaceutical company. Manufacturing for such specialty medications typically occurs across several high-tech facilities globally, including major sites in Ireland and the United States, to ensure supply for international markets.

AbbVie was originally formed in 2013 as a spin-off from Abbott Laboratories. Since its inception, it has grown into one of the world's largest independent research-based biopharmaceutical companies, focusing on complex therapeutic areas like immunology and oncology.